Home ProductsCancer Treatment Steroids

Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic

Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic

    • Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic
    • Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic
  • Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic

    Product Details:

    Place of Origin: China
    Brand Name: Fulu
    Certification: ISO9001
    Model Number: 184475-35-2

    Payment & Shipping Terms:

    Minimum Order Quantity: Negotiable
    Price: Negotiable
    Packaging Details: Discreet and tight safe packing for customs pass guaranteed
    Delivery Time: Within 24 hours after payment
    Payment Terms: T/T, , MoneyGram, Bit-coin
    Supply Ability: Mass stock
    Contact Now
    Detailed Product Description
    CAS: 184475-35-2 Name: Gefitinib
    MW: 386.47 Purity: 98%min
    Grade: Pharmaceutical Grade Chemical Properties: Off-White Solid
    High Light:

    anti cancer drugs

    ,

    prohormones bodybuilding

    Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic

     

    Basic info

     

    Product name: Gefitinib , Iressa
    Alias: GEFITINIB; AKOS 91371; n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; ZD 1839; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; Gefitinib(TINIBS); Gefitinib, Iressa, ZD1839; Gefitinib Base
    CAS RN: 184475-35-2
    Molecular formula: C22H24ClFN4O3
    Molecular weight: 446.9024

     

    Description


    Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nm, in NR6W cells.

     

    COA

     

    Tests Specification Results
    Appearance Slight white to white crystalline powder White crystalline powder
    Identification IR(1) Conforms to the refence Conforms to the refence
    Melting Point 194.0~198.0°C 196.0~197.0°C
    Water(KF) ≤0.30% 0.05%
    Assay (HPLC) ≥99.0% 99.9%
    Individual Purity (HPLC ) ≤0.20% 0.09%
    Conclusion

    Conform with company standard

     

    Application

     

    Gefitinib is a kind of selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
    The recommended treatment dose of adult is 250 mg of (1 tablet) with 1 time per day through orally administration, either in empty stomach or together with food.


    If you have difficulty in swallowing, you can disperse the tablets into a half cup of drinking water (non-carbonated beverages). Make sure to avoid using other kinds of liquid. Cast tablets into the water and stir until the complete dispersion of the tablet in the water (takes about 10 minutes) without the necessity of crushing. Immediately drink the liquid, and use half glass of water to rinse the cup, drink again. Alternatively, you can also administrate this drug solution through the nose - stomach tube.


    There is no necessity in adjusting the administrated dosage of the drug: age, weight, gender, race, renal function, and moderate to severe liver function dysfunction caused by hepatic metastasis.


    Dose adjustment

     

    when patients can't tolerate the diarrhea or skin adverse reactions, you can tackle this issue through short-term suspension (up to 14 days) of the treatment and then restore the dose of 250 mg per day.

     

    Recommended Antineoplastic products

     

    Product name CAS No.
    Lapatinib 231277-92-2
    Dasatinib 302962-49-8
    Axitinib 319460-85-0
    Gefitinib 184475-35-2
    Sunitinib Malate 341031-54-7
    Erlotinib hydrochloride 183319-69-9
    Doxorubicin hydrochloride 25316-40-9
    Mitomycin C 50-07-7
    Tegafur 17902-23-7
    Cisplatin 15663-27-1
    Vincristine sulfate 2068-78-2
    Melphalan 148-82-3
    Nimustine hydrochloride 55661-38-6
    Gemcitabine 95058-81-4
    Paclitaxel 33069-62-4
    Docetaxel 114977-28-5
    (Podophyllotoxin)nsc24818 518-28-5

     

    Gefitinib Iressa 184475-35-2 Cancer Treatment Steroids for Antineoplastic

    Contact Details
    SuZhou FuLu Biotech Co.,Ltd

    Contact Person: tony

    Tel: +8618115486572

    Send your inquiry directly to us (0 / 3000)